s-1743 has been researched along with Neoplasms* in 3 studies
2 trial(s) available for s-1743 and Neoplasms
Article | Year |
---|---|
Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.
Retrospective data suggest that gastric acid reduction by proton pump inhibitors (PPIs) impairs the dissolution and subsequent absorption of capecitabine, and thus potentially reduces the capecitabine exposure. Therefore, we examined prospectively the effect of esomeprazole on the pharmacokinetics of capecitabine. In this randomized crossover study, patients with cancer were assigned to 2 sequence groups, each consisting of 3 phases: capecitabine with esomeprazole administration 3 hours before (phase A), capecitabine alone (phase B), and capecitabine concomitant with cola and esomeprazole co-administration 3 hours before (phase C). The primary end point was the relative difference (RD) in exposure to capecitabine assessed by the area under the plasma concentration-time curve from zero to infinity (AUC Topics: Antimetabolites, Antineoplastic; Biological Availability; Capecitabine; Carbonated Beverages; Cross-Over Studies; Drug Interactions; Drug Monitoring; Esomeprazole; Female; Humans; Male; Middle Aged; Neoplasms; Netherlands; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its bioavailability. This study evaluated the effect of a potent CYP3A4 inhibitor, ketoconazole, and the proton pump inhibitor esomeprazole on the pharmacokinetics and safety of pazopanib and its metabolites.. In Arm A, patients received pazopanib 400 mg alone once daily for 7 days followed by pazopanib 400 mg plus ketoconazole 400 mg once daily for 5 days. In Arm B, patients received pazopanib 800 mg once daily for 7 days, followed by pazopanib 800 mg plus esomeprazole 40 mg once daily for 5 days, and then pazopanib alone on the last day.. Arm A enrolled 21 patients. In the presence of ketoconazole, mean area under the plasma concentration-time curve 24 h post-dose (AUC(0-24)) and mean maximum observed concentration (C max) of pazopanib increased by 66 and 45 %, respectively; mean AUC(0-24) and C max for pazopanib metabolites were lower or remained unchanged. Arm B enrolled 13 patients. In the presence of esomeprazole, mean pazopanib AUC(0-24) and C max decreased by 40 and 42 %, respectively; mean values of those parameters for metabolites of pazopanib also decreased.. Concomitant use of pazopanib with a strong CYP3A4 inhibitor should be avoided. If coadministration is necessary, pazopanib should be reduced to 400 mg. Concomitant use of pazopanib and proton pump inhibitors should also be avoided. Alternative dosing regimens that do not increase gastric pH at the time of pazopanib dosing should be considered. Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Esomeprazole; Female; Humans; Indazoles; Ketoconazole; Male; Middle Aged; Neoplasms; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2013 |
1 other study(ies) available for s-1743 and Neoplasms
Article | Year |
---|---|
Regulating Interactions Between Targeted Nanocarriers and Mononuclear Phagocyte System via an Esomeprazole-Based Preconditioning Strategy.
The mononuclear phagocyte system (MPS) presents a formidable obstacle that hampers the delivery of various nanopreparations to tumors. Therefore, there is an urgent need to improve the off-MPS targeting ability of nanomedicines. In the present study, we present a novel preconditioning strategy to substantially increase the circulation times and tumor targeting of nanoparticles by regulating nanocarrier-MPS interactions.. In vitro, the effect of different vacuolar H. In vitro, ESO was found to reduce the interactions between macrophages and c(RGDm7)-modified vesicles by interfering with the latter's lysosomal trafficking. Studies conducted in vivo confirmed that ESO pretreatment greatly decreased the liver and spleen distribution of the targeted vesicles, enhanced their tumor accumulation, and improved the therapeutic outcome of the drug-loaded nanomedicines.. Our findings indicate that ESO can regulate the nanoparticle-MPS interaction, which provides a feasible option for enhancing the off-MPS targeting of nanomedicines. Topics: A549 Cells; Animals; Antineoplastic Agents; Biological Transport; Cell Death; Cell Survival; Doxorubicin; Drug Carriers; Endocytosis; Esomeprazole; Humans; Lysosomes; MCF-7 Cells; Mice; Mice, Nude; Mononuclear Phagocyte System; Nanoparticles; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; RAW 264.7 Cells; Tissue Distribution; Vacuolar Proton-Translocating ATPases | 2020 |